NCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT04512235 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07081646 2026-03-13
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT06963216 2026-02-27
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Kedrion S.p.A.
Phase 3 Recruiting
NCT05184088 2025-11-25
CArdiag
Life Molecular Imaging SA
Phase 3 Recruiting
NCT05951049 2025-08-24
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Attralus, Inc.
Phase 2 Recruiting
NCT06097832 2025-07-10
NEXICART-2
Nexcella Inc.
Phase 1/2 Recruiting
NCT07055724 2025-07-09
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Nanjing IASO Biotechnology Co., Ltd.
Phase 2 Not yet recruiting
NCT05839626 2025-06-12
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1/2 Terminated